The launch of a world first wearable to measure central blood pressure and holders are happy to part with $60million in market capital. There are other early stage cancer diagnostic companies that are sitting at $200m MC and are unlikely to commercialise. It does take time for the market to understand what’s unfolding here. My advice is not to give away your shares for cheap. Cardiovascular disease is the number one killer and everyone prefers an early diagnosis when compared to treatment. Good luck to all holders.
Add to My Watchlist
What is My Watchlist?
